PMID: 8603012Feb 1, 1996Paper

t(3;21)(q26;q22) with AML1 rearrangement in a de novo childhood acute monoblastic leukaemia

British Journal of Haematology
B JohanssonF Mitelman

Abstract

t(3;21)(q26;q22) is a recurrent chromosomal abnormality in Philadelphia-positive chronic myeloid leukaemia in blast crisis and in treatment-related myelodysplastic syndrome and acute myeloid leukaemia. The molecular consequences of the t(3;21) are presently being unravelled; various transcripts between the AML1 gene in 21q22 and several unrelated genes, i.e. EAP, EVI1 and MDS1, in 3q26 are generated, resulting in the formation of a chimaeric transcription factor. The t(3;21) has only rarely been described in de novo leukaemias and never before in an acute leukaemia in a child. We here present the clinical, cytogenetic and molecular genetic findings in a boy with a de novo acute monoblastic leukaemia with t(3;21)(q26;q22) and AML1 rearrangement.

Citations

Sep 21, 2000·Leukemia Research·O AfonjaK Takeshita
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·G M CuencoR Ren
Mar 20, 2003·Cancer Investigation·Joäelle MichaudRobert Escher
Jan 13, 2006·European Journal of Haematology·Irén HaltrichStefan Imreh
Jul 1, 1997·European Journal of Haematology·T Leblanc, R Berger

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.